The company is demonstrably boosted the development of the new treatment for ATTR-CM, employing the compound. Initial trial data indicates potential benefits for those suffering by this severe illness. The emphasis underscores the company’s dedication to managing unmet healthcare needs in the cardiology arena. Attruby: BridgeBio's Novel Approach